ArticleSurgical case reports2026
Gallbladder Cancer with Human Chorionic Gonadotropin-Positive Tumor Cells: A Case Report and Review of the Literature.
Article in Surgical case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionHuman chorionic gonadotropin (HCG)-positive gallbladder cancer (GBC) is extremely rare and is associated with aggressive biological behavior and a poor prognosis. CASE PRESENTATION: An 84-year-old woman presented with locally advanced GBC with right hepatic artery encasement. After 2 courses of gemcitabine, cisplatin, and durvalumab therapy, tumor progression was controlled, and radical surgery was planned. The patient underwent an extended cholecystectomy with adjacent liver resection, extrahepatic bile duct resection, and biliary reconstruction via Roux-en-Y hepaticojejunostomy. Histological examination revealed adenocarcinoma containing HCG-positive tumor cells, and the pathological response to chemotherapy was poor. The patient developed a recurrence 9 months after surgery. Although chemotherapy was reintroduced after recurrence, the disease showed a limited response, and the patient eventually died 20 months after the initial diagnosis.
conclusionsHCG-positive GBC is a rare and aggressive disease. Although surgical resection may be feasible in selected cases, the prognosis remains poor.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.